Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC lowered its holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) by 23.9% in the fourth quarter, Holdings Channel.com reports. The fund owned 6,033 shares of the company’s stock after selling 1,896 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Travere Therapeutics were worth $54,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Signaturefd LLC increased its position in shares of Travere Therapeutics by 1,656.4% in the fourth quarter. Signaturefd LLC now owns 3,021 shares of the company’s stock valued at $27,000 after buying an additional 2,849 shares in the last quarter. Nisa Investment Advisors LLC increased its position in Travere Therapeutics by 968.1% during the 4th quarter. Nisa Investment Advisors LLC now owns 5,650 shares of the company’s stock worth $51,000 after purchasing an additional 5,121 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in Travere Therapeutics by 353.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,690 shares of the company’s stock worth $78,000 after purchasing an additional 6,773 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Travere Therapeutics during the 4th quarter worth about $137,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in Travere Therapeutics by 32.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,511 shares of the company’s stock worth $148,000 after purchasing an additional 4,007 shares in the last quarter.

Insider Buying and Selling

In related news, SVP William E. Rote sold 4,764 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $8.71, for a total transaction of $41,494.44. Following the transaction, the senior vice president now directly owns 80,720 shares of the company’s stock, valued at approximately $703,071.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Travere Therapeutics news, insider Peter Heerma sold 4,195 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $8.53, for a total value of $35,783.35. Following the transaction, the insider now directly owns 99,503 shares of the company’s stock, valued at approximately $848,760.59. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP William E. Rote sold 4,764 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $8.71, for a total value of $41,494.44. Following the completion of the transaction, the senior vice president now directly owns 80,720 shares in the company, valued at $703,071.20. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 34,773 shares of company stock valued at $300,625. Corporate insiders own 4.06% of the company’s stock.

Travere Therapeutics Trading Up 1.3 %

Shares of NASDAQ TVTX traded up $0.07 during midday trading on Tuesday, hitting $5.53. The stock had a trading volume of 1,315,865 shares, compared to its average volume of 1,272,650. The company has a fifty day moving average price of $7.23 and a 200 day moving average price of $7.64. The company has a market capitalization of $420.89 million, a price-to-earnings ratio of -3.43 and a beta of 0.58. The company has a quick ratio of 3.41, a current ratio of 3.47 and a debt-to-equity ratio of 1.88. Travere Therapeutics, Inc. has a 1-year low of $5.12 and a 1-year high of $22.75.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings results on Thursday, February 15th. The company reported ($1.16) EPS for the quarter, topping the consensus estimate of ($1.27) by $0.11. The firm had revenue of $45.06 million for the quarter, compared to analyst estimates of $41.25 million. Travere Therapeutics had a negative return on equity of 177.97% and a negative net margin of 56.02%. On average, analysts predict that Travere Therapeutics, Inc. will post -3.1 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on TVTX. Wells Fargo & Company lifted their price objective on Travere Therapeutics from $8.00 to $9.00 and gave the stock an “equal weight” rating in a research report on Friday, February 16th. Wedbush restated an “outperform” rating and issued a $13.00 price target on shares of Travere Therapeutics in a report on Wednesday, April 17th. Piper Sandler lifted their price target on Travere Therapeutics from $10.00 to $11.00 and gave the company a “neutral” rating in a report on Thursday, January 18th. HC Wainwright lifted their price target on Travere Therapeutics from $17.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Finally, Guggenheim restated a “neutral” rating on shares of Travere Therapeutics in a report on Wednesday, March 27th. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, Travere Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Travere Therapeutics Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.